Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.78 |
| ▸ | NPC1 | O15118 | 6/20 | 0.78 |
| ▸ | RAB9A | P51151 | 5/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7236943 | 1.00 | MAOA (0.78) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7234801 | 0.92 | MAOA (0.64) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7228607 | 0.88 | KDM4E (0.68) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7229420 | 0.88 | NPC1 (0.63) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL29958722 | 0.88 | MAOA (1.00) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL789950 | 0.88 | MAOA (1.00) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7237103 | 0.85 | MAOA (0.60) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL31260258 | 0.81 | MAOA (0.81) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7107987 | 0.81 | MAOA (0.81) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL7228147 | 0.80 | MAOA (0.67) | MAOANPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | claimed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | claimed |
| US-6559177-B2 | For therapy or inhibiting osteoporosis or inhibiting bone demineralization, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis in mammal | WYETH | 2003-05-06 | — | — | US | disclosed |
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183310-A1 | 5,11-dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents | ESR1, GPER1, ESR2 | MAOA 716/4885NPC1 1898/4885RAB9A 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.